High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection

Part of the Methods in Molecular Biology book series (MIMB, volume 1608)


Poly(ADP-ribose)polymerase 1 (PARP-1) protein became a popular target for treatment of several types of cancer. A number of PARP-1 inhibitors are currently in clinical trials. Most of them were designed competitors with NAD for a binding site on PARP-1 molecule. This strategy resulted in a discovery of mainly nucleotide-like PARP-1 inhibitors, which may target not only PARP-1 but also other pathways involving NAD and other nucleotides. Many cancer types demonstrate rapid development of resistance to NAD-like PARP-1 inhibitors. Thus, identification and characterization of new small molecules inhibit PARP-1 with high specificity and efficacy is important for the clinical research. We have proposed a new approach to screen libraries for new PARP-1 inhibitors based on histone H4-dependent PARP-1 activation. Beside identification of NAD competitors in a small molecules collection, this approach allows finding other classes of PARP-1 inhibitors that specifically disrupt H4-based PARP-1 activation or arrest inactive allosteric conformation of PARP-1. Here, we present an adaptation of this approach for a large-scale high-throughput screen.

Key words

PARP-1 PARP-1 activation PARP-1 inhibitor Poly(ADP-ribose) Library of small molecule inhibitors High-throughput colorimetric assay 



The research was supported by grants from the National Institutes of Health (R01 DK082623) to A.V.T.


  1. 1.
    Satoh MS, Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356(6367):356–358CrossRefPubMedGoogle Scholar
  2. 2.
    Kim MY, Mauro S, Gevry N, Lis JT, Kraus WL (2004) NAD-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119:803–814CrossRefPubMedGoogle Scholar
  3. 3.
    Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1–20CrossRefPubMedGoogle Scholar
  4. 4.
    Virag L, Szabo C (2002) The therapeutic potential of Poly(ADP-Ribose) polymerase inhibitors. Pharmacol Rev 54:375–429CrossRefPubMedGoogle Scholar
  5. 5.
    Kotova E, Pinnola AD, Tulin AV (2011) Small-molecule collection and high-throughput colorimetic assay to identify PARP-1 inhibitors. Methods Mol Biol 780:491–516CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Thomas C, Ji Y, Kotova E, Lodhi N, Pinnola AD, Golovine K, Makhov P, Pechenkina K, Kolenko V, Tulin AV (2016) New generation non-NAD-like PARP-1 inhibitors effectively eliminate drug resistant tumors in vivo. EBioMedicine . doi: 10.1016/j.ebiom.2016.10.001pii: S2352-3964(16)30456-XGoogle Scholar
  7. 7.
    Haince JF, Poirier GG, Kirkland JB. Nonisotopic methods for determination of poly(ADP-ribose) levels and detection of poly(ADP-ribose) polymerase. Curr Protoc Cell Biol. 2004 Feb; Chapter 18: Unit18.7.Google Scholar
  8. 8.
    Luger K, Rechsteiner TJ, Richmond TJ (1999) Expression and purification of recombinant histones and nucleosome reconstitution. Methods Mol Biol 119:1–16PubMedGoogle Scholar
  9. 9.
    Luger K, Rechsteiner TJ, Richmond TJ (1999) Preparation of nucleosome core particle from recombinant histones. Methods Enzymol 304:3–19CrossRefPubMedGoogle Scholar
  10. 10.
    Monti D et al (1994) Cell death protection by 3-aminobenzamide and other poly(ADP- ribose)polymerase inhibitors: different effects on human natural killer and lymphokine activated killer cell activities. Biochem Biophys Res Commun 199:525–530CrossRefPubMedGoogle Scholar
  11. 11.
    Banasik M et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569–1575PubMedGoogle Scholar
  12. 12.
    Zhang JH et al (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73CrossRefPubMedGoogle Scholar
  13. 13.
    Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11(3):247–252CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Cancer Biology ProgramFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations